ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)

Completed

Conditions: Macular Edema

Interventions: Drug: dexamethasone 700 ㎍ intravitreal implant

First Posted Date: 2014-07-11

Last Posted Date: 2016-06-01

Lead Sponsor: Allergan

Target Recruit Count: 200

Registration Number: NCT02188173

Locations: 🇺🇸
Raj Maturi, MD PC, Indianapolis, Indiana, United States
🇺🇸
Texas Retina Associates, Arlington, Arlington, Texas, United States
🇺🇸
Bay Area Retina Associates, Walnut Creek, California, United States

and more 15 locations

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Phase 2

Completed

Conditions: Macular Edema

Interventions: Drug: ranibizumab
Drug: abicipar pegol
Other: sham procedure

First Posted Date: 2014-07-10

Last Posted Date: 2015-07-14

Lead Sponsor: Allergan

Target Recruit Count: 151

Registration Number: NCT02186119

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

Phase 2

Completed

Conditions: Macular Degeneration

Interventions: Drug: abicipar pegol
Drug: ranibizumab
Other: sham procedure

First Posted Date: 2014-07-04

Last Posted Date: 2017-04-25

Lead Sponsor: Allergan

Target Recruit Count: 25

Registration Number: NCT02181504

Locations: 🇯🇵
Nihon University Hospital, Chiyoda-ku,Tokyo, Japan
🇯🇵
1 Fukushima Medical University, Fukushima-shi, Japan
🇯🇵
Kyushu University Hospital, Kita-ku, Fukuoka-shi Fukuoka, Japan

and more 8 locations

Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®

Completed

Conditions: Macular Edema
Retinal Vein Occlusion

Interventions: Other: No Intervention

First Posted Date: 2014-07-04

Last Posted Date: 2015-05-25

Lead Sponsor: Allergan

Target Recruit Count: 43

Registration Number: NCT02181530

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Phase 2

Completed

Conditions: Macular Degeneration

Interventions: Drug: ranibizumab
Drug: abicipar pegol
Other: sham procedure

First Posted Date: 2014-07-04

Last Posted Date: 2016-05-17

Lead Sponsor: Allergan

Target Recruit Count: 25

Registration Number: NCT02181517

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

Phase 4

Completed

Conditions: Glabellar Lines
Facial Rhytides
Crow's Feet Lines
Nasolabial Fold

Interventions: Biological: onabotulinumtoxinA
Drug: bimatoprost ophthalmic solution 0.03%
Device: JUVÉDERM® ULTRA XC
Device: JUVÉDERM® ULTRA PLUS XC
Device: JUVÉDERM® VOLUMA® XC

First Posted Date: 2014-06-27

Last Posted Date: 2019-01-09

Lead Sponsor: Allergan

Target Recruit Count: 116

Registration Number: NCT02176356

A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area

Not Applicable

Completed

Conditions: Infra-orbital Skin Depressions

Interventions: Device: VOLBELLA® with lidocaine

First Posted Date: 2014-06-27

Last Posted Date: 2019-04-16

Lead Sponsor: Allergan

Target Recruit Count: 80

Registration Number: NCT02176421

An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder

Completed

Conditions: Urinary Incontinence
Urinary Bladder, Overactive

Interventions: Biological: botulinum toxin Type A

First Posted Date: 2014-06-11

Last Posted Date: 2016-04-18

Lead Sponsor: Allergan

Target Recruit Count: 515

Registration Number: NCT02161159

Locations: 🇩🇪
Andreas Reinhard Wicht, Sangerhausen, Germany
🇩🇪
Franz Hirschle, Singen, Germany
🇩🇪
Universitätsklinikum Münster, Münster, Germany

and more 50 locations

AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis

Phase 3

Completed

Conditions: Conjunctivitis, Allergic

Interventions: Drug: AGN-229666
Drug: Olopatadine
Drug: Vehicle to AGN-229666

First Posted Date: 2014-06-11

Last Posted Date: 2019-04-17

Lead Sponsor: Allergan

Target Recruit Count: 240

Registration Number: NCT02161146

A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: AGN-223575 Vehicle
Drug: AGN-223575 Formulation A
Drug: AGN-223575 Formulation B
Drug: AGN-223575 Formulation C

First Posted Date: 2014-06-04

Last Posted Date: 2016-04-12

Lead Sponsor: Allergan

Target Recruit Count: 51

Registration Number: NCT02155543

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy